Business
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
− Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter.Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026.Ongoing partnering and strategic discussions with pharmaceutical companies and corporate advisers
About this update from Alterity Therapeutics Ltd.
[{"type":"image","alt":"ALTERITY THERAPEUTICS LIMITED","displaySize":"","headline":null,"caption":"ALTERITY THERAPEUTICS LIMITED","className":"","disableSlideshowImg":false,"size":{"original":{"width":222,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/5761c8df20b76a3904e54a7775315c62"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aH_lC7vKS4YC2ZvHbgCTDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5761c8df20b76a3904e54a7775315c62","width":222,"height":56}},"lazy":false},{"type":"text","content":"− Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced −","length":87,"tagName":"p"},{"type":"text","content":"Highlights","length":10,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter.","length":164,"tagName":"p"}]},{"val":[{"type":"text","content":"Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026.","length":140,"tagName":"p"}]},{"val":[{"type":"text","content":"Ongoing partnering and strategic discussions with pharmaceutical companies and corporate advisers to explore non-dilutive pathways to fund Phase 3 development.","length":159,"tagName":"p"}]},{"val":[{"type":"text","content":"Board and executive leadership strengthened to support Alterity through its next stage of clinical development, partnering and commercial planning.","length":147,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash balance of A$49.2 million at 31 December 2025.","length":51,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":661,"olType":false},{"type":"text","content":"MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 December 2025 (Q2 FY26).","length":402,"tagName":"p"},{"type":"text","content":"David Stamler, M.D., Chief Executive Officer of Alterity Therapeutics, comment...